In this newly created role, Klein will be responsible for the company’s scientific direction in toxicology and dermatology services and their operational processes. He will drive the growth of Sinclair’s business model and foster positive relationships with new and current customers.
 
Klein joins Sinclair Research from EP Technologies LLC in Akron, Ohio, where he directed preclinical research including discovery, toxicology and management of active transdermal technology. He held a similar position at Noven Pharmaceuticals working with passive transdermal technology, and has more than 15 years of industry experience.
 

“Jeff is an exciting new addition to the Sinclair research staff. In addition to his extensive experience in general toxicology and program management, he significantly enhances our scientific depth in the area of dermatology. Jeff will be an invaluable resource for clients developing products in this area,” said G. Alex Wakefield, Sinclair’s vice president of research and operations.